Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
2023-05-23 17:25
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
2023-05-18 11:53
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
2023-05-18 02:47
Antengene Announces NDA Submission for XPOVIO® in Indonesia
2023-05-17 08:30
Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO
2023-04-27 08:30
Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
2023-04-17 20:22
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
2023-03-29 08:30
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
2023-03-28 21:40
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
2023-03-20 15:20
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
2023-03-14 12:29
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
2023-01-03 14:10
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)
2022-12-27 08:30
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
2022-12-23 08:30
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
2022-12-09 08:30
Antengene Appoints Amily Zhang as its Chief Medical Officer
2022-12-08 08:30
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
2022-11-15 16:51
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
2022-11-11 08:30
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
2022-11-07 14:38
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China
2022-11-02 20:07
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
2022-10-31 20:22
1
2
3
4
5
7